KIDNEY CANCER
Clinical trials for KIDNEY CANCER explained in plain language.
Never miss a new study
Get alerted when new KIDNEY CANCER trials appear
Sign up with your email to follow new studies for KIDNEY CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New cancer drug trial halted early – what we know
Disease control TerminatedThis early-stage study tested a new drug called AUR106 in 21 adults with advanced cancers (lung, stomach, bladder, kidney, colon, or esophagus) that had come back or spread. The main goal was to find a safe dose and check how the drug moves through the body. The study was stopped…
Matched conditions: KIDNEY CANCER
Phase: PHASE1 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated May 26, 2026 03:10 UTC
-
Experimental cancer drug trial halted after early testing
Disease control TerminatedThis study tested a new drug called TAK-500, alone or with pembrolizumab, in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The goal was to check safety and see if the drug could shrink tumors. The trial was terminated early, so results are limited.
Matched conditions: KIDNEY CANCER
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated May 26, 2026 03:06 UTC
-
New drug cocktail for advanced kidney cancer shows early promise, but trial halted
Disease control TerminatedThis study tested a new drug (NKT2152) combined with two other medicines (palbociclib and sasanlimab) in people with advanced clear cell kidney cancer that had worsened after prior treatments. The goal was to see if the combination was safe and could shrink tumors. The trial was …
Matched conditions: KIDNEY CANCER
Phase: PHASE2 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 03:03 UTC
-
New pill shows promise in battling advanced kidney cancer
Disease control TerminatedThis trial tested an oral drug called NKT2152 in 120 people with advanced clear cell kidney cancer that had worsened after other treatments. The goal was to find the safest dose and see if it could shrink tumors. The study was stopped early, but results may help guide future trea…
Matched conditions: KIDNEY CANCER
Phase: PHASE1, PHASE2 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
New Breathing-Memory combo targets PTSD in terminal cancer patients
Symptom relief TerminatedThis study tested a technique that helps people with advanced cancer and their partners organize traumatic memories and practice slow breathing to reduce PTSD symptoms. The approach aimed to shift how the brain processes trauma, moving from emotional reactions to more controlled …
Matched conditions: KIDNEY CANCER
Phase: PHASE2 • Sponsor: Centre Oscar Lambret • Aim: Symptom relief
Last updated May 26, 2026 03:17 UTC